
Prof. Michael Lin
1.6K posts

Prof. Michael Lin
@MichaelLinLab
Stanford Neurobiology and Bioengineering Precision molecular design / synbiochem. Also @michaelzlin




With all due respect, I'd like to offer a few points of clarification. First, I have no issue with "shortcut models." In fact, many of my own papers use relatively simple models to solve important real-world problems. If a simpler model ultimately proves capable of capturing complex cellular biology and helping cure disease, I'd be delighted. Science should reward what works, not what is most sophisticated. Second, terms like virtual cells, foundation models, and world models are high-level concepts that describe a class of models rather than a specific algorithm. Similar terminology has emerged naturally in computer vision and NLP as the field evolved. I think it's reasonable to adopt analogous concepts in biology as we explore whether they can unlock similar advances. Whether these ideas ultimately live up to their promise is, of course, an empirical question. Rigorous validation will decide. This is exactly what my original post is about. Healthy skepticism is essential, but so is giving ambitious new directions the opportunity to prove (or disprove) themselves. I don't think we should dismiss a promising research direction simply because the terminology sounds aspirational 🙏🙏


New chemogenetic tool! nature.com/articles/s4139…





Over a 32-year career as an #HHMIInvestigator, @harvardmed’s Connie Cepko helped transform how we understand the retina, and how blindness might be treated. Her advice? "If you have a novel idea you believe in, go for it." bit.ly/4gN9Zqp




We report many proteins not predicted by the genetic code. They are stable & abundant O( 10³ ) copies / cell. Generative mechanisms include codon-anticodon mismatches & RNA modifications. Their abundance depends on codon frequency & protein stability. biorxiv.org/content/10.110…


Don’t get fooled: these designs are still far from zero-shot therapeutic biologics. BoltzProt-1 does not remove the need for downstream optimization, but it can give you a meaningful head start by reducing the time and cost required to reach strong starting points for your therapeutic program.


AF3 source code is now open source (aka Apache 2.0)! 😎 Though not the weights... 🙃 github.com/google-deepmin…


SCOOP: Roche’s Genentech underwent another round of layoffs this week in its early research and development group, Endpoints News has learned, which included shuttering two research units and the departure of several senior researchers. My latest here: endpoints.news/exclusive-gene…





